hVIVO plc

("hVIVO, the "Company" or the "Group")

Grant of awards under Long Term Incentive Plan

London, UK - 29 May 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces that on 28 May 2026, the Company awarded 10,159,068 options under the hVIVO Long Term Incentive Plan 2024 to certain senior management, including its Chief Executive Officer and Chief Financial Officer as set out in the table below. The award is over ordinary shares of £0.001 ("Ordinary Shares") in the form of options to acquire Ordinary Shares at nominal value ("LTIP Awards").

The LTIP Awards will vest on the third anniversary of grant subject to meeting a minimum absolute total shareholder return (TSR) of 10% CAGR and mid-single digit £ million adjusted EBITDA,  weighted equally, over the three-year period ending 31 December 2028.

25% of the LTIP Awards will vest on meeting the minimum threshold performance criteria outlined above, with vesting thereafter on a straight-line basis up to meeting a maximum performance target which would be achieved in the event of a 20% absolute TSR being met and a significant increase in adjusted EBITDA from the minimum threshold number.

The awards are subject to malus and clawback provisions. In making its determination in relation to the achievement of any performance target or condition under these Rules, the Remuneration Committee may, in line with the UK Corporate Governance Code, exercise its discretion to override formulaic outcomes. This includes, without limitation, to reflect overall corporate performance, the value created for shareholders, or where the business has suffered an exceptional negative event.

For further information please contact:

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain. 

Notes to Editors

hVIVO plc (AIM: HVO) is a purpose-built, full-service international clinical development partner and the global leader in human challenge trials, serving seven of the world's ten largest biopharma companies.

The Company has an end-to-end platform designed to bring important medicines to patients faster: spanning preclinical strategy, first‑in‑human studies, Phase II patient trials and specialist laboratory services, delivered through a large participant database, wholly owned sites and laboratories across the UK and Germany.

With a combined Group heritage of more than 100 years, hVIVO delivers an accelerated pathway to clinical proof-of-concept through four integrated service lines: Consulting, Clinical Trials, Human Challenge Trials, and Laboratories.

·    Consulting provides expert-led preclinical and clinical strategy, encompassing non-clinical, clinical, CMC, pharmacokinetics, data management, biostatistics, and regulatory support to guide trial design, execution, and interpretation.

·    Clinical Trials offers Phase I/II CRO services, Phase II/III site services across the UK and Germany, and specialist recruitment through FluCamp, Europe's largest recruitment database.

·    Human Challenge Trials leverages hVIVO's state-of-the-art quarantine facility in London - the largest of its kind worldwide - to deliver fast, controlled, high-quality efficacy data through guaranteed viral exposure.

·    Laboratories provides cutting-edge virology and immunology laboratory services, including biobanking and sample storage, supporting both challenge trials and standalone client studies.

The information set out below is provided in accordance with the requirements of Regulation 19(3) of the EU Market Abuse Regulation No 596/2014: